1
|
Kuang K, Li C, Maksut F, Ghosh D, Vinck R, Wang M, Poupon J, Xiang R, Li W, Li F, Wang Z, Du J, Teulade-Fichou MP, Gasser G, Bombard S, Jia T. A G-quadruplex-binding platinum complex induces cancer mitochondrial dysfunction through dual-targeting mitochondrial and nuclear G4 enriched genome. J Biomed Sci 2024; 31:50. [PMID: 38741159 DOI: 10.1186/s12929-024-01041-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 04/22/2024] [Indexed: 05/16/2024] Open
Abstract
BACKGROUND G-quadruplex DNA (G4) is a non-canonical structure forming in guanine-rich regions, which play a vital role in cancer biology and are now being acknowledged in both nuclear and mitochondrial (mt) genome. However, the impact of G4-based targeted therapy on both nuclear and mt genome, affecting mt function and its underlying mechanisms remain largely unexplored. METHODS The mechanisms of action and therapeutic effects of a G4-binding platinum(II) complex, Pt-ttpy, on mitochondria were conducted through a comprehensive approaches with in vitro and in vivo models, including ICP-MS for platinum measurement, PCR-based genetic analysis, western blotting (WB), confocal microscope for mt morphology study, extracellular flux analyzer, JC1 and Annexin V apoptosis assay, flow cytometry and high content microscope screening with single-cell quantification of both ROS and mt specific ROS, as well as click-chemistry for IF study of mt translation. Decipher Pt-ttpy effects on nuclear-encoded mt related genes expression were undertaken via RNA-seq, Chip-seq and CUT-RUN assays. RESULTS Pt-ttpy, shows a highest accumulation in the mitochondria of A2780 cancer cells as compared with two other platinum(II) complexes with no/weak G4-binding properties, Pt-tpy and cisplatin. Pt-ttpy induces mtDNA deletion, copy reduction and transcription inhibition, hindering mt protein translation. Functional analysis reveals potent mt dysfunction without reactive oxygen species (ROS) induction. Mechanistic study provided first evidence that most of mt ribosome genes are highly enriched in G4 structures in their promoter regions, notably, Pt-ttpy impairs most nuclear-encoded mt ribosome genes' transcription through dampening the recruiting of transcription initiation and elongation factors of NELFB and TAF1 to their promoter with G4-enriched sequences. In vivo studies show Pt-ttpy's efficient anti-tumor effects, disrupting mt genome function with fewer side effects than cisplatin. CONCLUSION This study underscores Pt-ttpy as a G4-binding platinum(II) complex, effectively targeting cancer mitochondria through dual action on mt and nuclear G4-enriched genomes without inducing ROS, offering promise for safer and effective platinum-based G4-targeted cancer therapy.
Collapse
Affiliation(s)
- Keli Kuang
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Chunyan Li
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Fatlinda Maksut
- CNRS-UMR9187, INSERM U1196, PSL-Research University, 91405, Orsay, France
- CNRS-UMR9187, INSERM U1196, Université Paris Saclay, 91405, Orsay, France
| | - Deepanjan Ghosh
- CNRS-UMR9187, INSERM U1196, PSL-Research University, 91405, Orsay, France
- CNRS-UMR9187, INSERM U1196, Université Paris Saclay, 91405, Orsay, France
| | - Robin Vinck
- Chimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, F-75005, Paris, France
| | - Maolin Wang
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Joël Poupon
- Hôpital Lariboisière (AP-HP), Laboratoire de Toxicologie Biologique, 2 rue Ambroise Paré, 75475, Paris, France
| | - Run Xiang
- Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
| | - Wen Li
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Fei Li
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Zhu Wang
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Junrong Du
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China
| | - Marie-Paule Teulade-Fichou
- CNRS-UMR9187, INSERM U1196, PSL-Research University, 91405, Orsay, France
- CNRS-UMR9187, INSERM U1196, Université Paris Saclay, 91405, Orsay, France
| | - Gilles Gasser
- Chimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, F-75005, Paris, France
| | - Sophie Bombard
- CNRS-UMR9187, INSERM U1196, PSL-Research University, 91405, Orsay, France.
- CNRS-UMR9187, INSERM U1196, Université Paris Saclay, 91405, Orsay, France.
| | - Tao Jia
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, 610041, Chengdu, China.
- CNRS-UMR9187, INSERM U1196, PSL-Research University, 91405, Orsay, France.
- CNRS-UMR9187, INSERM U1196, Université Paris Saclay, 91405, Orsay, France.
| |
Collapse
|
2
|
Petrov N, Lee HS, Liskovykh M, Teulade-Fichou MP, Masumoto H, Earnshaw WC, Pommier Y, Larionov V, Kouprina N. Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells. Oncotarget 2021; 12:1444-1456. [PMID: 34316326 PMCID: PMC8310675 DOI: 10.18632/oncotarget.28020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 06/22/2021] [Indexed: 11/25/2022] Open
Abstract
Telomerase/telomere-targeting therapy is a potentially promising approach for cancer treatment because even transient telomere dysfunction can induce chromosomal instability (CIN) and may be a barrier to tumor growth. We recently developed a dual-HAC (Human Artificial Chromosome) assay that enables identification and ranking of compounds that induce CIN as a result of telomere dysfunction. This assay is based on the use of two isogenic HT1080 cell lines, one carrying a linear HAC (containing telomeres) and the other carrying a circular HAC (lacking telomeres). Disruption of telomeres in response to drug treatment results in specific destabilization of the linear HAC. Results: In this study, we used the dual-HAC assay for the analysis of the platinum-derived G4 ligand Pt-tpy and five of its derivatives: Pt-cpym, Pt-vpym, Pt-ttpy, Pt(PA)-tpy, and Pt-BisQ. Our analysis revealed four compounds, Pt-tpy, Pt-ttpy, Pt-vpym and Pt-cpym, that induce a specific loss of a linear but not a circular HAC. Increased CIN after treatment by these compounds correlates with the induction of double-stranded breaks (DSBs) predominantly localized at telomeres and reflecting telomere-associated DNA damage. Analysis of the mitotic phenotypes induced by these drugs revealed an elevated rate of chromatin bridges (CBs) in late mitosis and cytokinesis. These terpyridine platinum-derived G4 ligands are promising compounds for cancer treatment.
Collapse
Affiliation(s)
- Nikolai Petrov
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Hee-Sheung Lee
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Mikhail Liskovykh
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Marie-Paule Teulade-Fichou
- Chemistry and Modelling for the Biology of Cancer, CNRS UMR 9187-INSERM U1196 Institute Curie, Research Center, Campus University Paris-Saclay, Orsay, France
| | - Hiroshi Masumoto
- Laboratory of Chromosome Engineering, Department of Frontier Research and Development, Kazusa DNA Research Institute, Kisarazu, Chiba 292-0818, Japan
| | - William C Earnshaw
- Wellcome Centre for Cell Biology, School of Biological Sciences, King's Buildings, University of Edinburgh, Max Born Crescent, Edinburgh EH9 3BF, Scotland
| | - Yves Pommier
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Vladimir Larionov
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Natalay Kouprina
- Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| |
Collapse
|
3
|
Alessandrini I, Recagni M, Zaffaroni N, Folini M. On the Road to Fight Cancer: The Potential of G-quadruplex Ligands as Novel Therapeutic Agents. Int J Mol Sci 2021; 22:5947. [PMID: 34073075 PMCID: PMC8198608 DOI: 10.3390/ijms22115947] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 05/27/2021] [Accepted: 05/27/2021] [Indexed: 12/14/2022] Open
Abstract
Nucleic acid sequences able to adopt a G-quadruplex conformation are overrepresented within the human genome. This evidence strongly suggests that these genomic regions have been evolutionary selected to play a pivotal role in several aspects of cell biology. In the present review article, we provide an overview on the biological impact of targeting G-quadruplexes in cancer. A variety of small molecules showing good G-quadruplex stabilizing properties has been reported to exert an antitumor activity in several preclinical models of human cancers. Moreover, promiscuous binders and multiple targeting G-quadruplex ligands, cancer cell defense responses and synthetic lethal interactions of G-quadruplex targeting have been also highlighted. Overall, evidence gathered thus far indicates that targeting G-quadruplex may represent an innovative and fascinating therapeutic approach for cancer. The continued methodological improvements, the development of specific tools and a careful consideration of the experimental settings in living systems will be useful to deepen our knowledge of G-quadruplex biology in cancer, to better define their role as therapeutic targets and to help design and develop novel and reliable G-quadruplex-based anticancer strategies.
Collapse
Affiliation(s)
| | | | | | - Marco Folini
- Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via G.A. Amadeo 42, 20133 Milan, Italy; (I.A.); (M.R.); (N.Z.)
| |
Collapse
|
4
|
Ali S, Lombardi EP, Ghosh D, Jia T, Vitry G, Saker L, Poupon J, Teulade-Fichou MP, Nicolas A, Londono-Vallejo A, Bombard S. Pt-ttpy, a G-quadruplex binding platinum complex, induces telomere dysfunction and G-rich regions DNA damage. Metallomics 2021; 13:6280987. [PMID: 34021581 DOI: 10.1093/mtomcs/mfab029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 05/11/2021] [Accepted: 05/13/2021] [Indexed: 11/14/2022]
Abstract
Pt-ttpy (tolyl terpyridin-Pt complex) covalently binds to G-quadruplex (G4) structures in vitro and to telomeres in cellulo via its Pt moiety. Here, we identified its targets in the human genome, in comparison to Pt-tpy, its derivative without G4 affinity, and cisplatin. Pt-ttpy, but not Pt-tpy, induces the release of the shelterin protein TRF2 from telomeres concomitantly to the formation of DNA damage foci at telomeres but also at other chromosomal locations. γ-H2AX chromatin immunoprecipitation (ChIP-seq) after treatment with Pt-ttpy or cisplatin revealed accumulation in G- and A-rich tandemly repeated sequences, but not particularly in potential G4 forming sequences. Collectively, Pt-ttpy presents dual targeting efficiency on DNA, by inducing telomere dysfunction and genomic DNA damage at specific loci.
Collapse
Affiliation(s)
- Samar Ali
- INSERM UMRS 1007, Université de Paris, 75006 Paris, France
| | - Emilia Puig Lombardi
- Institut Curie, PSL Research University, CNRS UMR3244, Sorbonne Université, Telomeres and Cancer lab, 75005 Paris, France
| | - Deepanjan Ghosh
- Institut Curie, CNRS UMR9187-INSERMU1196, CMBC, 91405 Orsay, France.,Institut Curie, CNRS UMR9187-INSERMU1196, Université Paris-Saclay, 91405 Orsay, France
| | - Tao Jia
- Institut Curie, CNRS UMR9187-INSERMU1196, CMBC, 91405 Orsay, France.,Institut Curie, CNRS UMR9187-INSERMU1196, Université Paris-Saclay, 91405 Orsay, France
| | | | - Lina Saker
- INSERM UMRS 1007, Université de Paris, 75006 Paris, France
| | - Joël Poupon
- Hôpital Lariboisière, Laboratoire de Toxicologie Biologique, 2 rue Ambroise Paré, 75475 Paris, France
| | - Marie-Paule Teulade-Fichou
- Institut Curie, CNRS UMR9187-INSERMU1196, CMBC, 91405 Orsay, France.,Institut Curie, CNRS UMR9187-INSERMU1196, Université Paris-Saclay, 91405 Orsay, France
| | - Alain Nicolas
- Institut Curie, PSL Research University, CNRS UMR3244, Sorbonne Université, Telomeres and Cancer lab, 75005 Paris, France
| | - Arturo Londono-Vallejo
- Institut Curie, PSL Research University, CNRS UMR3244, Sorbonne Université, Telomeres and Cancer lab, 75005 Paris, France
| | - Sophie Bombard
- Institut Curie, CNRS UMR9187-INSERMU1196, CMBC, 91405 Orsay, France.,Institut Curie, CNRS UMR9187-INSERMU1196, Université Paris-Saclay, 91405 Orsay, France
| |
Collapse
|
5
|
Morel E, Beauvineau C, Naud-Martin D, Landras-Guetta C, Verga D, Ghosh D, Achelle S, Mahuteau-Betzer F, Bombard S, Teulade-Fichou MP. Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA. Molecules 2019; 24:molecules24030404. [PMID: 30678027 PMCID: PMC6385020 DOI: 10.3390/molecules24030404] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 01/18/2019] [Accepted: 01/22/2019] [Indexed: 01/23/2023] Open
Abstract
Guanine-rich DNA can form four-stranded structures called G-quadruplexes (G4s) that can regulate many biological processes. Metal complexes have shown high affinity and selectivity toward the quadruplex structure. Here, we report the comparison of a panel of platinum (II) complexes for quadruplex DNA selective recognition by exploring the aromatic core around terpyridine derivatives. Their affinity and selectivity towards G4 structures of various topologies have been evaluated by FRET-melting (Fluorescence Resonance Energy Transfert-melting) and Fluorescent Intercalator Displacement (FID) assays, the latter performed by using three different fluorescent probes (Thiazole Orange (TO), TO-PRO-3, and PhenDV). Their ability to bind covalently to the c-myc G4 structure in vitro and their cytotoxicity potential in two ovarian cancerous cell lines were established. Our results show that the aromatic surface of the metallic ligands governs, in vitro, their affinity, their selectivity for the G4 over the duplex structures, and platination efficiency. However, the structural modifications do not allow significant discrimination among the different G4 topologies. Moreover, all compounds were tested on ovarian cancer cell lines and normal cell lines and were all able to overcome cisplatin resistance highlighting their interest as new anticancer drugs.
Collapse
Affiliation(s)
- Elodie Morel
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Claire Beauvineau
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Delphine Naud-Martin
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Corinne Landras-Guetta
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Daniela Verga
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Deepanjan Ghosh
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Sylvain Achelle
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- University Rennes, CNRS, ISCR-UMR 6226, F-35000 Rennes, France.
| | - Florence Mahuteau-Betzer
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Sophie Bombard
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| | - Marie-Paule Teulade-Fichou
- Institut Curie, PSL Research University, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
- Université Paris Sud, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, F-91405 Orsay, France.
| |
Collapse
|